We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in Thermo Fisher Scientific (TMO - Free Report) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today?
Thermo Fisher Scientific's Business In-Depth
With that in mind, let's take a look at Thermo Fisher Scientific's main business drivers.
Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In November 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb. 3, 2014, Thermo Fisher acquired Life Technologies Corporation.
The company serves four principal end markets: pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics. It reports operations through four segments.
The Life Sciences Solutions segment, representing 23.3% of total revenues in 2025, was added post the acquisition of Life Technologies. It incorporates the majority of the former Life Technologies and Thermo Fisher’s Biosciences businesses. In 2025, this business registered growth of 7.7% from the 2024 level.
In September 2025, the company completed the acquisition of Solventum’s Purification & Filtration business. In July 2024, Thermo Fisher acquired Olink, a provider of next-generation proteomics solutions.
The Analytical Instruments segment, which represented 17% of total revenues in 2025, provides instruments, consumables, software and services across chromatography and mass spectrometry, chemical analysis, and electron microscopy. In 2025, the business registered revenue growth of 1.2% from the 2024 level.
The Specialty Diagnostics (SD) segment represents 10.5% of total revenues, formed after the acquisition of Phadia, serves customers in healthcare and clinical laboratories with a portfolio of diagnostic test kits, reagents and instruments used to increase the speed and accuracy of diagnoses to improve patient care. In 2025, this business registered growth of 3.6% from the 2024 level.
Laboratory Products and Biopharma Services, represents 55.8% of total revenues. It has been renamed to reflect the inclusion of the PPD acquisition. PPD has been referred to as a clinical research business within this segment. In 2025, this business registered growth of 3.6% from the 2024 level.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Thermo Fisher Scientific a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in November 2016 would be worth $4,734.73, or a gain of 373.47%, as of November 2, 2026, and this return excludes dividends but includes price increases.
Compare this to the S&P 500's rally of 256.47% and gold's return of 187.75% over the same time frame.
Going forward, analysts are expecting more upside for TMO.
Thermo Fisher benefits from recovering pharma and biotech spending, wider customer adoption and gains across its research and services portfolio. Bioproduction, Pharma Services and clinical research provide multiple sources of growth. Clario and the filtration business deepen capabilities, while new instruments and AI-enabled workflows strengthen customer relationships. Better organic demand and disciplined execution prompted another increase in management's revenue and earnings outlook. Still, academic and government spending remains subdued, and diagnostics growth is uneven. Currency swings, tariffs and acquisition-related debt add uncertainty. Competition also requires sustained investment in innovation and commercialization. These risks offset the benefits of recovering demand and support a Neutral view of the shares.
Shares have gained 6.44% over the past four weeks and there have been 11 higher earnings estimate revisions for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in Thermo Fisher Scientific (TMO - Free Report) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today?
Thermo Fisher Scientific's Business In-Depth
With that in mind, let's take a look at Thermo Fisher Scientific's main business drivers.
Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In November 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb. 3, 2014, Thermo Fisher acquired Life Technologies Corporation.
The company serves four principal end markets: pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics. It reports operations through four segments.
The Life Sciences Solutions segment, representing 23.3% of total revenues in 2025, was added post the acquisition of Life Technologies. It incorporates the majority of the former Life Technologies and Thermo Fisher’s Biosciences businesses. In 2025, this business registered growth of 7.7% from the 2024 level.
In September 2025, the company completed the acquisition of Solventum’s Purification & Filtration business. In July 2024, Thermo Fisher acquired Olink, a provider of next-generation proteomics solutions.
The Analytical Instruments segment, which represented 17% of total revenues in 2025, provides instruments, consumables, software and services across chromatography and mass spectrometry, chemical analysis, and electron microscopy. In 2025, the business registered revenue growth of 1.2% from the 2024 level.
The Specialty Diagnostics (SD) segment represents 10.5% of total revenues, formed after the acquisition of Phadia, serves customers in healthcare and clinical laboratories with a portfolio of diagnostic test kits, reagents and instruments used to increase the speed and accuracy of diagnoses to improve patient care. In 2025, this business registered growth of 3.6% from the 2024 level.
Laboratory Products and Biopharma Services, represents 55.8% of total revenues. It has been renamed to reflect the inclusion of the PPD acquisition. PPD has been referred to as a clinical research business within this segment. In 2025, this business registered growth of 3.6% from the 2024 level.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Thermo Fisher Scientific a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in November 2016 would be worth $4,734.73, or a gain of 373.47%, as of November 2, 2026, and this return excludes dividends but includes price increases.
Compare this to the S&P 500's rally of 256.47% and gold's return of 187.75% over the same time frame.
Going forward, analysts are expecting more upside for TMO.
Thermo Fisher benefits from recovering pharma and biotech spending, wider customer adoption and gains across its research and services portfolio. Bioproduction, Pharma Services and clinical research provide multiple sources of growth. Clario and the filtration business deepen capabilities, while new instruments and AI-enabled workflows strengthen customer relationships. Better organic demand and disciplined execution prompted another increase in management's revenue and earnings outlook. Still, academic and government spending remains subdued, and diagnostics growth is uneven. Currency swings, tariffs and acquisition-related debt add uncertainty. Competition also requires sustained investment in innovation and commercialization. These risks offset the benefits of recovering demand and support a Neutral view of the shares.
Shares have gained 6.44% over the past four weeks and there have been 11 higher earnings estimate revisions for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.